The technology could help make stool sample screening more comprehensive and facilitate the identification of parasitic findings for subsequent expert review.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

16 VHIR professionals have participated in specialized training in innovation and entrepreneurship in health, culminating in a project competition and the awarding of the first prize for the best pitch.

The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).

The network will work in the prevention of cognitive and physical decline, early and digital diagnosis, the development of technologies to support independent living, support for carers and families, as well as new therapies and biomarkers.

The funds will enable the company to accelerate the preclinical phase and explore the application of its immunotherapy in other types of cancer.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

The study will validate the safety of a novel topical ocular administration route for sitagliptin.

The program aims to foster an innovation-driven culture within the VHIR, improve the management of projects with transfer potential, and promote leading innovation profiles within research groups.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The Stroke Research and the Neurovascular Diseases groups lead innovative research projects in both clinical and translational areas.

It’s one of Europe’s leading biotechnology events and one of the largest in the world.

The event has promoted collaboration within the VHIR innovation ecosystem and has highlighted the innovation model to facilitate capital investment for our spin-offs.

The team will develop a new medical tool to facilitate the removal of blood clots in blood vessels after a stroke in a safer and more effective manner.

Areas of interest include the development of new drugs, medical devices and digital health solutions, as well as new therapies and diagnostic technologies.

FIT is an initiative aimed at funding projects developed at VHIR with high impact and market transfer potential.

A retrospective study has been carried out with data from 11,000 patients to train artificial intelligence algorithms and adapt the Nora mobile application to different patient profiles.

Transaction expands Formation Bio's immunology pipeline with Phase 1 ready drug candidate.

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.

The aim of the initiative is to improve the management of innovation projects and their reach to patients and promote innovative and entrepreneurial culture.

This certification pushes our system towards a more mature model, with defined processes, clear metrics and a real focus on impact.

The report by the Botin Foundation and Inveniam places the Institute only behind the CSIC and the UB.

This is a structured system that prioritizes projects with the greatest potential to ensure their viability and maximize the chances of success in their clinical application and commercialization, with a focus on benefiting patients.

A key initiative that connects researchers with a network of more than 20 external mentors who are experts in various fields within the ecosystem.